Back to state act
Description
On 5 June 2020, the Norwegian Medicines Agency introduced a notification requirement on exports of rivaroxaban, edoxaban, Bacillus Calmette-Guérin, rasburicase and lacosamide following the COVID-19 ou...
Sign in to see full description
Intervention Details
Intervention Type
Export licensing requirement
MAST Chapter
P: Export-related measures (incl. subsidies)
Implementation date
05 Jun 2020
Revocation date
01 Jul 2023
Implementation level
National
Affected flow
Outward
Announced as temporary
Yes
Eligible firms
all
Affected Trading Partners
Table
Affected Sectors
Sign in to access 1 sectors
Affected Products
Sign in to access 4 products
Threads
See all
This intervention is not part of any Thread yet.